Clinical Trials on Cancers, Ovary in Russian Federation

Total 819 results

Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Exelixis
Ipsen

Active, not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

Hong Kong, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, ... and more
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer

Belgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Small Cell Lung Cancer

United States, Canada, Germany, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Czechia, India, Japan, Russian Federation, Turkey, China, United Kingdom, Argentina
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Japan, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331)

Lung Cancer

United States, Belgium, Brazil, China, Denmark, Italy, Japan, Norway, Romania, Spain, Australia, Austria, Chile, Czechia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Russian Federation, Switzerland, Taiwan, United...
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Non-Small Cell Lung Cancer

Poland, United States, Brazil, France, Guatemala, Hungary, Japan, Korea, Republic of, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
R-Pharm

Terminated

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (IXAMPLE2)

Endometrial Cancer

Brazil, Czech Republic, Italy, Mexico, Russian Federation, Sweden, United Kingdom, United States, Spain, Canada, Denmark, France, Peru, Belgium, Hungary, Norway, Argentina, Australia, Greece
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Non-small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, China, Hong Kong, France, Russian Federation, Netherlands, Japan, Spain, Italy, Belgium, Vietnam, Malaysia, Thailand, Germany, Singapore
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Squamous Non-Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Brazil, Canada, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, P... and more
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
AbbVie

Completed

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Metastatic Breast Cancer

United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Norway, Po... and more
Janssen Pharmaceutica N.V., Belgium

Completed

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Prostate Cancer

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
Hoffmann-La Roche

Terminated

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Gastric Cancer

United States, China, Korea, Republic of, Canada, Belgium, Brazil, Finland, Guatemala, Italy, Poland, Spain, Turkey, United Kingdom, Czechia, Hungary, Russian Federation, Argentina, France, Germany, Japan, Malaysia, Mexico, Panama, Peru, Philippin... and more
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Breast Cancer

United States, Poland, Ukraine, United Kingdom, Spain, Israel, Bulgaria, Romania, Serbia, South Africa, Russian Federation, Hungary, Lithuania, Netherlands, Latvia, Portugal, Estonia, France
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Merck KGaA, Darmstadt, Germany

Completed

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND)

Gastric Cancer

Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, Germany, China, Hungary, Romania, Japan, Hong Kong, Argentina, Austria, Belgium, Chile, Israel, Greece, Taiwan, Au... and more
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Estonia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, U... and more
Elevar Therapeutics

Completed

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (ANGEL)

Gastric Cancer | Gastric Adenocarcinoma

United States, United Kingdom, Korea, Republic of, France, Taiwan, Japan, Russian Federation, Germany, Italy, Poland, Romania, Ukraine
GlaxoSmithKline

Completed

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Small Cell Lung Cancer

United States, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Costa Rica, Czech Republic, Estonia, Finland, France, Germany, Honduras, Hungary, Italy, Jamaica, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Norw... and more
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
United Therapeutics

Completed

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Spain, Australia, Korea, Republic of, France, United Kingdom, Thailand, Malaysia, Hungary, Poland, Taiwan, Philippines, Hong Kong, Lithuania, Georgia, Bulgaria, India, Italy, Romania, Russian Federation, Slo... and more
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
Hoffmann-La Roche

Completed

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Breast Cancer

Spain, United Kingdom, Belgium, Austria, Brazil, France, Germany, Hungary, Italy, Thailand, Korea, Republic of, Hong Kong, Romania, Canada, Argentina, Czechia, Peru, Estonia, Mexico, Poland, Russian Federation, Croatia, Netherlands
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START)

Non-small Cell Lung Cancer

United States, Sweden, Australia, Czech Republic, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Germany, China, Poland, Romania, Denmark, Hong Kong, Canada, Austria, Belgium, Hungary, Israel, Nether... and more
Ferring Pharmaceuticals
Memorial Sloan Kettering Cancer Center; Duke Clinical Research Institute

Terminated

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE)

Prostate Cancer

United States, France, Canada, Czechia, Finland, Germany, Greece, Poland, Russian Federation, Slovakia, South Africa, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

Prostate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate Cancer

Hong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Canada, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Hungary, Spain, China, Brazil, France, Australia, Czechia, Germany, Israel, Canada, United Kingdom, Japan, Belgium, Romania, Italy, Poland, Lithuania, Korea, Republic of, Bulgaria, Estonia, Russian Federation
Amgen

Completed

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Cancer | Cataract | Prostate Cancer | Osteoporosis | Osteopenia | Low Bone Mineral Density

United States, Canada, Czechia, Poland, Russian Federation, Slovakia, Hungary, South Africa, Greece, Bulgaria, France, Ukraine, Australia, Latvia, India, Slovenia, New Zealand, Mexico
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer (HELOISE)

Gastric Cancer

Germany, Spain, China, Korea, Republic of, United Kingdom, Philippines, Russian Federation, United States, New Zealand, Hungary, Italy, South Africa, Turkey, Bosnia and Herzegovina, Serbia, Czech Republic, Poland, Portugal, ... and more
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

Gastric Cancer

United States, Australia, Belgium, Korea, Republic of, Russian Federation, Germany, Poland, Spain, Argentina, Austria, Brazil, Bulgaria, Chile, Estonia, France, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Sing... and more
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Cemiplimab in Adults With Cervical Cancer

Squamous Cell Carcinoma (SCC) | Recurrent or Metastatic, Platinum-refractory Cervical Cancer

Spain, Korea, Republic of, United States, United Kingdom, Taiwan, Brazil, Belgium, Australia, Italy, Canada, Japan, Greece, Poland, Russian Federation

Clinical Trials on Cancers, Ovary in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations